168 related articles for article (PubMed ID: 20018308)
21. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume.
Petit JH; Gluck C; Kiger WS; Laury Henry D; Karasiewicz C; Talcott JA; Berg S; Holupka EJ; Kaplan ID
Brachytherapy; 2007; 6(4):267-71. PubMed ID: 17959423
[TBL] [Abstract][Full Text] [Related]
22. Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy.
Tsai HK; Manola J; Abner A; Talcott JA; D'Amico AV; Beard C
Urol Oncol; 2005; 23(4):230-7. PubMed ID: 16018937
[TBL] [Abstract][Full Text] [Related]
23. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
24. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
Beyer DC; McKeough T; Thomas T
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
[TBL] [Abstract][Full Text] [Related]
25. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
[TBL] [Abstract][Full Text] [Related]
26. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
27. Dosimetric outcomes in prostate brachytherapy: is downsizing the prostate with androgen deprivation necessary?
Gibbons EP; Jacobs BL; Smith RP; Beriwal S; Krishna K; Benoit RM
Brachytherapy; 2009; 8(3):304-8. PubMed ID: 19217354
[TBL] [Abstract][Full Text] [Related]
28. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer.
Pinkawa M; Fischedick K; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Urology; 2006 Jul; 68(1):104-9. PubMed ID: 16806434
[TBL] [Abstract][Full Text] [Related]
29. Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation.
Stone NN; Stock RG; Unger P
Mol Urol; 2000; 4(3):163-8;discussion 169-70. PubMed ID: 11062370
[TBL] [Abstract][Full Text] [Related]
30. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
Tanaka N; Fujimoto K; Hirao Y; Asakawa I; Hasegawa M; Konishi N
Urology; 2009 Aug; 74(2):407-11. PubMed ID: 19376570
[TBL] [Abstract][Full Text] [Related]
31. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant Hormonal Therapy Improves the Outcomes of Patients Undergoing Radioactive Seed Implantation for Localized Prostate Cancer.
Stone NN; Stock RG
Mol Urol; 1999; 3(3):239-244. PubMed ID: 10851329
[TBL] [Abstract][Full Text] [Related]
33. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
[TBL] [Abstract][Full Text] [Related]
34. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
Stone NN; Stock RG
Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
[TBL] [Abstract][Full Text] [Related]
35. A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study.
Gujral S; Abrams P; Donovan JL; Neal DE; Brookes ST; Chacko KN; Wright MJ; Timoney AG; Peters TJ
J Urol; 2000 Jul; 164(1):59-64. PubMed ID: 10840425
[TBL] [Abstract][Full Text] [Related]
36. Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy.
Roeloffzen EM; van Vulpen M; Battermann JJ; van Roermund JG; Saibishkumar EP; Monninkhof EM
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):737-44. PubMed ID: 20888131
[TBL] [Abstract][Full Text] [Related]
37. Permanent prostate brachytherapy for Japanese men: results from initial 100 patients with prostate cancer.
Okaneya T; Nishizawa S; Nakayama T; Kamigaito T; Hashida I; Hosaka N
Int J Urol; 2007 Jul; 14(7):602-6. PubMed ID: 17645602
[TBL] [Abstract][Full Text] [Related]
38. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
Lehrer S; Cesaretti J; Stone NN; Stock RG
BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
[TBL] [Abstract][Full Text] [Related]
39. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.
Martin T; Röddiger S; Kurek R; Dannenberg T; Eckart O; Kolotas C; Heyd R; Rogge B; Baltas D; Tunn U; Zamboglou N
Radiother Oncol; 2004 Apr; 71(1):35-41. PubMed ID: 15066294
[TBL] [Abstract][Full Text] [Related]
40. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy.
Sarosdy MF
Cancer; 2004 Aug; 101(4):754-60. PubMed ID: 15305406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
